Business Wire

MORINAGA-MILK-INDUSTRY

30.5.2024 20:01:28 CEST | Business Wire | Press release

Share
Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, has announced a groundbreaking discovery in the fundamental research of Human-Residential Bifidobacteria (HRB). Through a joint collaboration with Kyoto University, the research has discovered that a specific type of bifidobacteria living in humans, also known as HRB, has the ability to convert precursors of a potentially harmful component into a beneficial metabolite. The research team has uncovered a previously unknown metabolic pathway utilized by the HRB species, converting indole, a potentially harmful compound, into the immunomodulatory metabolite indole-3-lactic acid (ILA). The findings, published in the prestigious journal "Gut Microbes" on May 5, 2024, underscore the unique capabilities of HRB as superior probiotics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530532346/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)

Research Background

The research focused on indole, a compound produced by certain intestinal bacteria, which is metabolized in the liver and converted into indoxyl sulfate, a typical urinary toxin. When renal function is impaired, indole and indoxyl sulfate can accumulate in the blood, leading to potential health issues, such as the progression of kidney dysfunction. The formation of indole, which is derived from tryptophan, an essential amino acid for humans, may lead to harmful impacts that are inevitable and pose significant health concerns. In collaboration with Kyoto University, Morinaga Milk’s new research aimed to investigate whether HRB strains could reduce the concentration of indole and transform it into a beneficial metabolite, and understand the underlying mechanism.

Groundbreaking Findings Backed HRB Superiority

  1. Reduction of Indole Concentration: The study revealed that a specific type of bifidobacteria living in humans, including Morinaga Milk’s HRB strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63 significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1).
  2. Conversion of Indole into Tryptophan (Trp) and Indole-3-Lactate (ILA): The research demonstrated that selected bifidobacterial strains, including Morinaga Milk’s HRB strains, can convert indole into tryptophan (Trp) and indole-3-lactate (ILA) (Figure 2). While tryptophan is a necessary amino acid, ILA has been identified as an immunomodulatory compound that supports intestinal and systemic immune health. This discovery marks a significant step forward in understanding how beneficial gut bacteria can transform harmful substances into compounds that promote health.
  3. Metabolic Pathway Elucidation: The study identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3). The researchers confirmed that selected bifidobacterial strains, including Morinaga Milk’s HRB strains can efficiently transform exogenous indole into ILA and Trp. This elucidation of the metabolic pathway provides a detailed understanding of the biochemical processes involved, highlighting the sophisticated mechanisms by which bifidobacteria contribute to gut health.
  4. Exclusive Presence in HRB: An extensive genome database search of 11,943 bacterial strains revealed that the co-occurrence of trpB and aldh genes is exclusive to HRB species. This specificity underlines the unique probiotic potential of these bifidobacteria in human health applications. The genomic analysis underscores the distinctiveness of HRB, positioning them as uniquely capable of performing these beneficial transformations.

Implications for Health

These findings highlight the potential of HRB strains, such as those commercialized by Morinaga Milk, in mitigating the harmful effects of indole by converting it into beneficial ILA. This novel function of bifidobacteria highlights their beneficial effects on human, where indole and its metabolites pose potential adverse health effects for individuals with high risks of chronic kidney disease. Moreover, the conversion of indole into tryptophan and ILA also suggests broader implications for overall gut health. Tryptophan is essential for protein synthesis and serves as a precursor for serotonin, a neurotransmitter that plays a critical role in mood regulation and overall well-being. The production of ILA, with its immunomodulatory properties, further supports the immune system, suggesting the additional health potentials of HRB as probiotics. These findings provide valuable insights into the reasons why HRB species thrive in the human intestinal tract and maintain a symbiotic relationship with the human host.

Continued Commitment to HRB Research

Morinaga Milk Industry remains dedicated to advancing our understanding of HRB and their health benefits. This discovery is a testament to our commitment to innovative research and developing high-quality, scientifically-backed probiotic products that contribute to human health and well-being. Our ongoing research endeavors aim to uncover even more ways in which HRB strains can benefit human health, reinforcing our position as a leader in the field of probiotics.

Embrace the Future: Aim Higher!

Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve an overseas sales ratio of 15% or more by the fiscal year ending March 2029. The company will continue its effort in developing and providing effective HRB probiotics with a higher level of safety and quality, aiming to strengthen its probiotic sales in the global marketplace to help achieve the goal.

About Morinaga Milk Industry

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530532346/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release

Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release

Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release

IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye